PT-141 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
PEF also won a federal lawsuit requiring the state to pay millions of dollars in overtime to PEF members, and reinstated the lawsuit in state court after the state appealed. Sheedy also undertook the union's first large-scale organizing campaigns since its formation. AFT, one of PEF's parent unions, assigned a full-time national organizer to help PEF organize health care workers in the private sector who worked for potential state contractors. But this plan backfired politically. In 1996, PEF won an election for 42 paraprofessional health care workers working for a private contractor at the Coxsackie Correctional Facility. This organizing drive was highly criticized by Sheedy's political opponents, who claimed the union's executive board did not approve the organizing effort and who argued that PEF should only be organizing professional (not paraprofessional) workers. Sheedy also fought openly with the PEF staff union. Ninety-six of PEF's 120 staff belonged to Local 9265 of the United Steelworkers of America and had been working without a contract for nine months by March 1996. The staff union complained that PEF refused to negotiate over layoffs and downsizing, demanded a 10 percent pay raise (with differential pay for downstate workers), and several position upgrades. Roger Benson, former chief of staff under PEF President Howard Shafer, supported the staff union publicly and strongly criticized Sheedy for his poor labor relations. PEF and its staff union finally settled their contract dispute in June 1996.
Specific activity (symbol a) is the activity per unit mass of a radionuclide and is a physical property of that radionuclide. It is usually given in units of becquerel per kilogram (Bq/kg), but another commonly used unit of specific activity is the curie per gram (Ci/g). 1 Ci/g = 37 TBq/kg. In the context of radioactivity, activity or total activity (symbol A) is a physical quantity defined as the number of radioactive transformations per second that occur in a particular radionuclide. The unit of activity is the becquerel (symbol Bq), which is defined equivalent to reciprocal seconds (symbol s−1). The older, non-SI unit of activity is the curie (Ci), which is 3.7×1010 radioactive decays per second (37 GBq). Another unit of activity is the rutherford (Rd), which is defined as 1×106 radioactive decays per second (1 MBq). The specific activity should not be confused with level of exposure to ionizing radiation and thus the exposure or absorbed dose, which is the quantity important in assessing the effects of ionizing radiation on humans. Since the probability of radioactive decay for a given radionuclide within a set time interval is fixed (with some slight exceptions, see changing decay rates), the number of decays that occur in a given time of a given mass (and hence a specific number of atoms) of that radionuclide is also a fixed (ignoring statistical fluctuations).
Joseph Robinette Biden Jr. was born on November 20, 1942, at St. Mary's Hospital in Scranton, Pennsylvania, to Catherine Eugenia "Jean" Biden (née Finnegan) and Joseph Robinette Biden Sr. He is the oldest child in a Catholic family of predominantly Irish descent. Biden has a sister, Valerie, and two brothers, James and Francis. Joseph Sr. had been wealthy, and the family purchased a home in the affluent Long Island suburb of Garden City, New York, in 1946. After he suffered business setbacks around the time Biden was seven years old, the family lived with Jean's parents in Scranton for several years. Scranton fell into economic decline during the 1950s, and Joseph Sr. could not find steady work. Beginning in 1953, when Biden was ten, the family lived in an apartment in Claymont, Delaware, before moving to a house in nearby Mayfield, Delaware. Joseph Sr. later became a successful used-car salesman, maintaining the family in a middle-class lifestyle. Growing up, Biden observed alcoholism in his family, deciding at a young age to be teetotal. At Archmere Academy in Claymont, Biden played baseball and was a standout halfback and wide receiver on the high school football team. Though a poor student, he was class president in his junior and senior years. He graduated in 1961. At the University of Delaware in Newark, Biden briefly played freshman football and received a Bachelor of Arts degree with a double major in history and political science in 1965. To overcome a childhood stutter, he memorized lines from Ralph Waldo Emerson and William Butler Yeats.
Sources: en.wikipedia.org
In City 17, Gordon Freeman and Alyx Vance (Merle Dandridge) have destroyed the Citadel's reactor. As it explodes, several vortigaunts (Louis Gossett Jr.) appear and extract Alyx. The G-Man (Michael Shapiro), who extracted Gordon from the explosion, is confronted by the vortigaunts and his psychic connection to Gordon is severed. Gordon awakens in the ruins of City 17, where he is rescued from a pile of rubble by Dog and reunited with Alyx. Alyx makes contact with Dr. Eli Vance (Robert Guillaume) and Dr. Isaac Kleiner (Harry S. Robins), who have escaped the city. Kleiner informs them that the Citadel's core will soon collapse and destroy the city. Gordon and Alyx proceed into the core to temporarily stabilize it. Alyx discovers that the Combine is attempting to accelerate its destruction to send a transmission back to their homeworld. She downloads a copy of the transmission and a video recorded by Judith Mossman (Michelle Forbes), in which she discusses the location of an unknown project before being subdued by a Combine attack. Gordon and Alyx board a Combine train to escape the Citadel, but it derails. They proceed underground and through the city streets, fighting past disorganized Combine forces and rampant Xen wildlife. Near a Combine-held train station, Gordon and Alyx reunite with Barney Calhoun (Michael Shapiro), to evacuate refugees from the city. They escort the refugees and take a different train out of City 17, escaping just as the reactor detonates, which delivers the Combine transmission.
Typical δDs for ice sheets in the polar regions range from around −400‰ to −300‰ (‰SMOW). Ice caps' δDs are affected by distance from open ocean, latitude, atmospheric circulation, and the amount of insolation and temperature. The temperature change affects the HIC of ice caps, so the HIC of ice can give estimates for the historical climate cycles such as the timelines for interglacial and glacial periods. [See section 7.2. Paleo-reconstruction for more details] The δDs of ice caps from 70 km south of Vostok Station and in East Antarctica are −453.7‰ and −448.4‰ respectively, and are shown on the map.
== United States price history == The ethacrynic acid tablet market had U.S. sales of approximately $17 million for the 12 months ending April 2020 according to IQVIA. National Average Drug Acquisition Cost data from the Centers for Medicare and Medicaid Services shows that the average price paid by retail pharmacies for an Edecrin 25 MG tablet was $5.24 as 11/28/13 by Bausch Health US, LLC, formerly Valeant Pharmaceuticals. The price from Bausch Health US, LLC increased to $21.72 per tablet as of 5/18/2016. In 2015, Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. As of September 19, 2018, the price for the generic equivalent was $10.01 per tablet from West-ward Pharmaceuticals Corp., Edenbridge Pharmaceuticals, LLC and Oceanside Pharmaceuticals. As of July 22, 2020 the price decreased to $3.45 with availability from additional generic manufacturers. As of February 17, 2021 the average price paid by pharmacies was $5.69 per 25 MG tablet with 10 generic manufacturers.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.